Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) Cost of Revenue (2019 - 2025)

Historic Cost of Revenue for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $4.1 million.

  • Biodesix's Cost of Revenue fell 174.68% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.2 million, marking a year-over-year increase of 1079.77%. This contributed to the annual value of $15.6 million for FY2024, which is 1970.02% up from last year.
  • As of Q3 2025, Biodesix's Cost of Revenue stood at $4.1 million, which was down 174.68% from $4.0 million recorded in Q2 2025.
  • Over the past 5 years, Biodesix's Cost of Revenue peaked at $18.2 million during Q1 2021, and registered a low of $2.5 million during Q4 2021.
  • In the last 5 years, Biodesix's Cost of Revenue had a median value of $3.6 million in 2022 and averaged $4.5 million.
  • Within the past 5 years, the most significant YoY rise in Biodesix's Cost of Revenue was 105230.87% (2021), while the steepest drop was 8298.53% (2021).
  • Over the past 5 years, Biodesix's Cost of Revenue (Quarter) stood at $2.5 million in 2021, then skyrocketed by 32.61% to $3.3 million in 2022, then rose by 2.06% to $3.4 million in 2023, then rose by 28.69% to $4.3 million in 2024, then dropped by 5.44% to $4.1 million in 2025.
  • Its Cost of Revenue was $4.1 million in Q3 2025, compared to $4.0 million in Q2 2025 and $3.7 million in Q1 2025.